CD5 and lymphoma: The disease showed an aggressive clinicalcourse and progressed through the R-CHOP chemotherapy, proving the fact that thesesubtypes of lymphomas are molecularly and clinically different from CD5− DLBCL.Whether more intensive chemotherapy like REPOCH or Hyper-CVAD would have benefittedfor these rare lymphomas is still a question of debate as there are no consensus inthe treatment regimens for these unique subtypes.